A stochastically curtailed two‐arm randomised phase II trial design for binary outcomes

作者: Martin Law , Michael J. Grayling , Adrian P. Mander

DOI: 10.1002/PST.2067

关键词:

摘要: Randomised controlled trials are considered the gold standard in trial design. However, phase II oncology with a binary outcome often single-arm. Although number of reasons exist for choosing single-arm trial, primary reason is that designs require fewer participants than their randomised equivalents. Therefore, development novel methodology makes more efficient value to community. This article introduces two-arm design includes stochastic curtailment (SC), allowing possibility stopping before final conclusions known certainty. In addition SC, proposed involves use block design, which allows investigators control interim analyses. approach compared existing also early stopping, through loss function comprised weighted sum characteristics. Comparisons made using an example from real trial. The comparisons show many possible functions, superior designs. Further, may be practical, by flexible One produces realisations when anticipated response rate low. this probability rejecting null hypothesis sensitive misspecification rate. considering II, we recommend preferred over other sequential

参考文章(42)
Sin-Ho Jung, Daniel J. Sargent, Randomized Phase II Clinical Trials Journal of Biopharmaceutical Statistics. ,vol. 24, pp. 802- 816 ,(2014) , 10.1080/10543406.2014.901343
A. Necchi, P. Giannatempo, L. Mariani, E. Farè, D. Raggi, M. Pennati, N. Zaffaroni, F. Crippa, A. Marchianò, N. Nicolai, M. Maffezzini, E. Togliardi, M. G. Daidone, A. M. Gianni, R. Salvioni, F. De Braud, PF-03446962, a fully-human monoclonal antibody against transforming growth-factor β (TGFβ) receptor ALK1, in pre-treated patients with urothelial cancer: an open label, single-group, phase 2 trial. Investigational New Drugs. ,vol. 32, pp. 555- 560 ,(2014) , 10.1007/S10637-014-0074-9
Adrian P. Mander, James M.S. Wason, Michael J. Sweeting, Simon G. Thompson, Admissible two-stage designs for phase II cancer clinical trials that incorporate the expected sample size under the alternative hypothesis. Pharmaceutical Statistics. ,vol. 11, pp. 91- 96 ,(2012) , 10.1002/PST.501
Myron N. Chang, Harry S. Wieand, Vivian T. Chang, The bias of the sample proportion following a group sequential phase II clinical trial Statistics in Medicine. ,vol. 8, pp. 563- 570 ,(1989) , 10.1002/SIM.4780080505
E. Seregni, M. Maccauro, C. Chiesa, L. Mariani, C. Pascali, V. Mazzaferro, F. De Braud, R. Buzzoni, M. Milione, A. Lorenzoni, A. Bogni, A. Coliva, S. Lo Vullo, E. Bombardieri, Treatment with tandem [90Y]DOTA-TATE and [177Lu]DOTA-TATE of neuroendocrine tumours refractory to conventional therapy European Journal of Nuclear Medicine and Molecular Imaging. ,vol. 41, pp. 223- 230 ,(2014) , 10.1007/S00259-013-2578-5
Paul M. Barr, Thomas P. Miller, Jonathan W. Friedberg, Derick R. Peterson, Andrea M. Baran, Megan Herr, Catherine M. Spier, Haiyan Cui, Denise J. Roe, Daniel O. Persky, Carla Casulo, Jamie Littleton, Mark Schwartz, Soham Puvvada, Terry H. Landowski, Lisa M. Rimsza, Robert T. Dorr, Richard I. Fisher, Steven H. Bernstein, Margaret M. Briehl, Phase 2 study of imexon, a prooxidant molecule, in relapsed and refractory B-cell non-Hodgkin lymphoma Blood. ,vol. 124, pp. 1259- 1265 ,(2014) , 10.1182/BLOOD-2014-04-570044
Richard Simon, Optimal two-stage designs for phase II clinical trials. Controlled Clinical Trials. ,vol. 10, pp. 1- 10 ,(1989) , 10.1016/0197-2456(89)90015-9
Guogen Shan, Changxing Ma, Alan D. Hutson, Gregory E. Wilding, Randomized two-stage Phase II clinical trial designs based on Barnard's exact test. Journal of Biopharmaceutical Statistics. ,vol. 23, pp. 1081- 1090 ,(2013) , 10.1080/10543406.2013.813525
Manish R. Sharma, Kristen Wroblewski, Blase N. Polite, James A. Knost, James A. Wallace, Sanjiv Modi, Bethany G. Sleckman, David Taber, Everett E. Vokes, Walter M. Stadler, Hedy L. Kindler, Dasatinib in previously treated metastatic colorectal cancer: a phase II trial of the University of Chicago Phase II Consortium Investigational New Drugs. ,vol. 30, pp. 1211- 1215 ,(2012) , 10.1007/S10637-011-9681-X
A. O. Ayanlowo, D. T. Redden, Stochastically curtailed phase II clinical trials Statistics in Medicine. ,vol. 26, pp. 1462- 1472 ,(2007) , 10.1002/SIM.2653